文献速递银屑病与炎症性皮肤病

布罗达鲁单抗与富马酸酯类在中重度斑块状银屑病初治患者中的头对头4期随机试验(CHANGE)

A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-12-23

这项24周、开放标签、评估者设盲、多中心、头对头4期试验将210例未接受过系统治疗的中重度斑块状银屑病患者按1:1随机分配至布罗达鲁单抗210 mg皮下注射组或口服富马酸酯类(FAE)组。第24周时,布罗达鲁单抗组达到PASI75和sPGA 0/1的患者比例均显著高于FAE组(81.0% vs. 38.1%和64.8% vs. 20.0%,均P < 0.001),且达到PASI75和PASI90的中位时间更短。布罗达鲁单抗组不良事件发生率低于FAE组,未发现新的安全性信号。

要点

  • 布罗达鲁单抗第24周PASI75达81.0%,显著优于FAE的38.1%(P < 0.001)。
  • 布罗达鲁单抗sPGA 0/1达64.8%,显著优于FAE的20.0%(P < 0.001)。
  • 布罗达鲁单抗起效更快,达到PASI75和PASI90的中位时间均显著短于FAE。

核心结论

  • 在未接受过系统治疗的中重度斑块状银屑病患者中,布罗达鲁单抗24周疗效显著优于FAE,且起效更快、不良事件发生率更低。

研究设计与样本

  • 24周、开放标签、评估者设盲、多中心、头对头4期随机试验,210例患者按1:1随机分配至布罗达鲁单抗210 mg皮下注射组或口服FAE组。

主要发现

  • 第24周布罗达鲁单抗组PASI75为81.0%,FAE组为38.1%(P < 0.001)。
  • 第24周布罗达鲁单抗组sPGA 0/1为64.8%,FAE组为20.0%(P < 0.001)。
  • 布罗达鲁单抗组达到PASI75和PASI90的中位时间分别为4.1周和7.4周,FAE组分别为16.4周和24.4周(均P < 0.0001)。
  • 布罗达鲁单抗组不良事件发生率为616.4事件/100暴露年,FAE组为1195.8事件/100暴露年。
  • 布罗达鲁单抗未检测到新的安全性信号。

临床怎么用

  • 对于未接受过系统治疗的中重度斑块状银屑病患者,布罗达鲁单抗可作为起效快且疗效优于FAE的系统治疗选择。

局限性

  • 本研究为开放标签设计,仅评估24周疗效与安全性,长期数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brodalumab is a fully human monoclonal immunoglobulin IgG2 antibody that binds to the human IL-17 receptor subunit A and by that inhibits the biologic action of IL-17A, IL-17F, IL-17C and IL-17E. Therapy with fumaric acid esters (FAE) is a well established and widely used first-line systemic treatment for subjects with moderate-to-severe plaque psoriasis. OBJECTIVES: To compare brodalumab to FAE in terms of clinical efficacy, patient-reported outcomes and safety in subjects with moderate-to-severe plaque psoriasis who were naïve to systemic treatment. METHODS: Eligible subjects were randomized 1 : 1 to 210 mg brodalumab injections or oral FAE according to product label in this 24-week, open-label, assessor-blinded, multi-centre, head-to-head phase 4 trial. The primary endpoints were having PASI75 and having sPGA score of 0 or 1 (sPGA 0/1). Subjects with missing values for the primary endpoints were considered non-responders. RESULTS: A total of 210 subjects were randomized. 91/105 subjects completed brodalumab treatment and 58/105 subjects completed FAE treatment. At Week 24, significantly more subjects in the brodalumab group compared to the FAE group had PASI75 (81.0% vs. 38.1%, P < 0.001) and sPGA 0/1 (64.8% vs. 20.0%, P < 0.001). In the brodalumab group, the median time to both PASI75 and to PASI90 was significantly shorter than in the FAE group (4.1 weeks vs. 16.4 weeks, and 7.4 weeks vs. 24.4 weeks, respectively, P < 0.0001 for both). The rate of adverse events was lower in subjects treated with brodalumab compared to subjects treated with FAE (616.4 vs. 1195.8 events per 100 exposure years). No new safety signals were detected for brodalumab. CONCLUSIONS: Brodalumab was associated with rapid and significant improvements in signs and symptoms of moderate-to-severe plaque psoriasis, with a superior efficacy profile to what was observed with FAE in systemic-naïve subjects over 24 weeks.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pinter A, Hoffmann M, Reich K, et al. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). J Eur Acad Dermatol Venereol. 2020. PMID: 32939860. doi:10.1111/jdv.16932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。